论文部分内容阅读
目的:观察恩替卡韦联合双歧杆菌三联活菌胶囊治疗慢性乙型肝炎后肝硬化患者临床疗效和安全性。方法:慢性乙型肝炎后肝硬化患者86例随机分为观察组43例与对照组43例。对照组给予恩替卡韦胶囊治疗,观察组在对照组基础上加用双歧杆菌三联活菌胶囊。两组疗程均为3个月。比较两组疗效,治疗前后胆红素(TBi L)、AST、ALT等肝功能指标和透明质酸(HA)、Ⅲ型前胶原(PCⅢ)及层黏蛋白(LN)等肝纤维化指标变化,及药品不良反应发生情况。结果:观察组治疗总有效率明显高于对照组(P<0.05)。治疗后,两组患者TBi L、AST、ALT水平,以及HA、PCⅢ、LN水平均较前明显降低(P<0.05);且观察组患者上述指标水平显著低于对照组(P<0.05)。两组均未见药品不良反应发生。结论:恩替卡韦联合双歧杆菌三联活菌胶囊治疗慢性乙型肝炎后肝硬化疗效显著,可改善患者肝功能和肝纤维化,且安全性好。
Objective: To observe the clinical efficacy and safety of entecavir combined with Bifidobacterium triple viable capsule in the treatment of patients with chronic hepatitis B after liver cirrhosis. Methods: Eighty-six patients with chronic hepatitis B cirrhosis were randomly divided into observation group (43 cases) and control group (43 cases). The control group was treated with entecavir capsules. The observation group was given Bifidobacterium triple viable capsule on the basis of the control group. Two groups of treatment are 3 months. The liver function indexes such as bilirubin (TBiL), AST and ALT before and after treatment were compared between the two groups. Changes of hepatic fibrosis indexes such as HA, PCIII and laminin , And the occurrence of adverse drug reactions. Results: The total effective rate of observation group was significantly higher than that of control group (P <0.05). After treatment, TBiL, AST and ALT levels, HA, PCIII and LN levels in both groups were significantly lower than those in the two groups before treatment (P <0.05). The levels of these indexes in the observation group were significantly lower than those in the control group (P <0.05). No adverse drug reactions occurred in both groups. Conclusion: The efficacy of entecavir combined with Bifidobacterium triple viable capsule in the treatment of chronic hepatitis B has obvious curative effect on liver cirrhosis. It can improve liver function and liver fibrosis and has good safety.